Ibtesam Alzaroq Emnia
Egypt
Title: STUDY OF LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASE1 (LPCAT1) EXPRESSION IN UROTHELIAL CARCINOMAOF THE URINARY BLADDER
Biography
Biography: Ibtesam Alzaroq Emnia
Abstract
Background:Bladder cancer is the second most frequent malignancy of the urinary tract after prostate cancer.The involvement of lipids in carcinogenesis has been reported in some malignancies. The recently recognized lysophosphatidylcholineacyltransferase 1 (LPCAT1); the most important enzyme in membrane biogenesis, has been currently implicated in carcinogenesis. The role of LPCAT1in bladder cancer development and progression and its impact on patients’ outcome has not been previously investigated.
Methods:In this study, we evaluated the immunohistochemical expression of LPCAT1 in 60 cases of bladder urothelial carcinoma in relation to other clinicopathological features of the tumor as well as patients' prognosis.
Results:LPCAT1was expressed in all studied cases of urothelial carcinomas with two distinct patterns of staining, a strong nuclear expression pattern significantly detected in low grade tumors and a weak cytoplasmic staining with nuclear membrane accentuation significantly seen in high grade tumors. Furthermore, nuclear staining pattern correlated significantly with tumor recurrence, progression and patient's survival. Although tumor stage, vascular invasion, angiogenesis, percent of necrosis and mitotic count in the studied cases were significantly related to tumor recurrence and progression, no significant correlation was detected between any of those variables and LPCAT1 expression. In Multivariate cox regression model including significant variables, LPCAT1 nuclear expression emerged as independent predictor of early tumor recurrence.
Conclusions:We concluded that LPCAT1 protein is likely involved in bladder tumor carcinogenesis, recurrence and progression, and it provides a new perspective for targeted therapy.